
Bristol-Myers Squibb Company
BMYHealthcare|Drug Manufacturers - General|US
$62.14
-0.99 (-1.57%)
DCF Value
$239.82
Graham Number
$34.15
Cash / Share
$6.16
Financials
Financial Snapshot
Market Cap
$127.02B
Enterprise Value
$162.26B
Revenue (TTM)
$50.03B
Net Income (TTM)
$9.24B
Cash & Investments
$12.58B
Net Cash
-$32.23B
Free Cash Flow (TTM)
$9.29B
Operating CF (TTM)
$10.65B
Debt/Equity
1.91
Cash Runway & Burn Rate
Company is cash-flow positive.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $6.35B | $6.81B | $8.76B | $15.39B | $16.45B | $17.22B | $9.25B | $12.28B | $10.86B | $10.67B | $12.58B | |
| Operating Cash Flow | $3.06B | $5.28B | $7.07B | $8.21B | $14.05B | $16.21B | $13.07B | $13.86B | $15.19B | $14.16B | $10.65B | |
| Free Cash Flow | $1.84B | $4.22B | $6.12B | $7.37B | $13.30B | $15.23B | $11.95B | $12.65B | $13.94B | $12.85B | $9.29B | |
| Capital Expenditure | -$1.22B | -$1.05B | -$951.0M | -$836.0M | -$753.0M | -$973.0M | -$1.12B | -$1.21B | -$1.25B | -$1.31B | -$1.37B | |
| Financing Cash Flow | -$2.65B | -$4.08B | -$3.54B | $7.62B | -$1.15B | -$16.22B | -$16.96B | -$9.42B | $5.13B | -$10.35B | -$11.44B |
R&D Spending
R&D (TTM)
$10.56B
R&D Intensity
21.1%
R&D Growth vs Prior
+6.1%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $19.43B | $20.78B | $22.56B | $26.14B | $42.52B | $46.38B | $46.16B | $45.01B | $48.30B | $48.20B | $50.03B | |
| R&D Expense | $5.01B | $6.47B | $6.33B | $6.15B | $11.14B | $10.20B | $9.51B | $9.30B | $11.16B | $9.95B | $10.56B | |
| R&D % of Revenue | 25.8% | 31.1% | 28.1% | 23.5% | 26.2% | 22.0% | 20.6% | 20.7% | 23.1% | 20.6% | 21.1% | |
| SG&A | $4.98B | $4.75B | $4.55B | $4.87B | $7.66B | $7.69B | $7.81B | $7.77B | $8.41B | $7.27B | $7.32B |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $19.43B | $20.78B | $22.56B | $26.14B | $42.52B | $46.38B | $46.16B | $45.01B | $48.30B | $48.20B | $50.03B | |
| Cost of Revenue | $4.97B | $6.01B | $6.47B | $8.08B | $11.77B | $9.94B | $10.14B | $10.69B | $13.97B | $13.94B | $15.39B | |
| Gross Profit | $14.46B | $14.76B | $16.09B | $18.07B | $30.75B | $36.45B | $36.02B | $34.31B | $34.33B | $34.26B | $34.64B | |
| R&D | $5.01B | $6.47B | $6.33B | $6.15B | $11.14B | $10.20B | $9.51B | $9.30B | $11.16B | $9.95B | $10.56B | |
| SG&A | $4.98B | $4.75B | $4.55B | $4.87B | $7.66B | $7.69B | $7.81B | $7.77B | $8.41B | $7.27B | $7.32B | |
| Operating Income | $4.47B | $3.45B | $5.11B | $5.91B | $2.18B | $8.54B | $9.10B | $8.20B | $5.89B | $13.72B | $13.05B | |
| Interest Expense | $167.0M | $196.0M | $183.0M | $656.0M | $1.42B | $1.33B | $1.23B | $1.17B | $1.95B | $1.89B | $1.65B | |
| Pretax Income | $5.92B | $5.13B | $5.97B | $4.97B | -$6.87B | $8.10B | $7.71B | $8.44B | -$8.38B | $9.33B | $11.33B | |
| Net Income | $4.46B | $1.01B | $4.92B | $3.44B | -$9.02B | $6.99B | $6.33B | $8.03B | -$8.95B | $7.05B | $9.24B | |
| EPS (Diluted) | 2.65 | 0.61 | 3.03 | 2.01 | -3.98 | 3.12 | 2.95 | 3.86 | -4.41 | 3.45 | 4.51 | |
| EBITDA | $6.46B | $6.12B | $6.79B | $7.38B | $4.93B | $20.12B | $19.22B | $19.37B | $3.17B | $15.23B | $15.15B | |
| Shares Out. (M) | 1680.00 | 1652.00 | 1637.00 | 1712.00 | 2258.00 | 2245.00 | 2146.00 | 2078.00 | 2027.00 | 2041.00 | 2053.00 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.24B | $5.42B | $6.91B | $12.35B | $14.55B | $13.98B | $9.12B | $11.46B | $10.35B | $10.21B | $9.57B | |
| Short-Term Investments | $2.11B | $1.39B | $1.85B | $3.05B | $1.90B | $3.24B | $130.0M | $816.0M | $513.0M | $464.0M | $3.01B | |
| Total Current Assets | $13.70B | $14.85B | $17.72B | $29.35B | $30.19B | $33.26B | $27.27B | $31.77B | $29.78B | $29.39B | $29.77B | |
| Total Assets | $33.71B | $33.55B | $34.99B | $129.94B | $118.48B | $109.31B | $96.82B | $95.16B | $92.60B | $90.04B | $88.77B | |
| Total Current Liabilities | $8.84B | $9.56B | $10.65B | $18.30B | $19.08B | $21.87B | $21.89B | $22.26B | $23.77B | $23.42B | $18.75B | |
| Long-Term Debt | $5.72B | $6.97B | $5.65B | $43.39B | $48.34B | $39.60B | $35.06B | $36.65B | $47.60B | $42.85B | $41.85B | |
| Total Liabilities | $17.36B | $21.70B | $20.86B | $78.25B | $80.60B | $73.31B | $65.70B | $65.67B | $76.22B | $71.53B | $65.37B | |
| Stockholders' Equity | $16.18B | $11.74B | $14.03B | $51.60B | $37.82B | $35.95B | $31.06B | $29.43B | $16.34B | $18.47B | $23.40B | |
| Retained Earnings | $33.51B | $31.16B | $34.06B | $34.47B | $21.28B | $23.82B | $25.50B | $28.77B | $14.91B | $16.90B | $21.19B |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $3.06B | $5.28B | $7.07B | $8.21B | $14.05B | $16.21B | $13.07B | $13.86B | $15.19B | $14.16B | $10.65B | |
| Capital Expenditure | -$1.22B | -$1.05B | -$951.0M | -$836.0M | -$753.0M | -$973.0M | -$1.12B | -$1.21B | -$1.25B | -$1.31B | -$1.37B | |
| Free Cash Flow | $1.84B | $4.22B | $6.12B | $7.37B | $13.30B | $15.23B | $11.95B | $12.65B | $13.94B | $12.85B | $9.29B | |
| Investing Cash Flow | $1.48B | -$66.0M | -$2.00B | -$9.91B | -$10.86B | -$538.0M | -$1.06B | -$2.29B | -$21.35B | -$4.13B | -$5.31B | |
| Financing Cash Flow | -$2.65B | -$4.08B | -$3.54B | $7.62B | -$1.15B | -$16.22B | -$16.96B | -$9.42B | $5.13B | -$10.35B | -$11.44B | |
| Issuance of Stock | $181.0M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$106.0M | -$128.0M | -$26.0M | |
| Repurchase of Stock | -$231.0M | -$2.47B | -$320.0M | -$7.30B | -$1.55B | -$6.29B | -$8.00B | -$5.16B | $0.00 | $0.00 | -$98.0M | |
| Net Debt Issuance | $110.0M | $991.0M | -$548.0M | $17.65B | $3.93B | -$6.18B | -$5.31B | $456.0M | $10.10B | -$5.17B | -$6.26B | |
| Stock Based Comp. | $205.0M | $199.0M | $221.0M | $441.0M | $779.0M | $583.0M | $457.0M | $518.0M | $507.0M | $553.0M | $552.0M | |
| Net Change in Cash | $1.85B | $1.18B | $1.49B | $5.91B | $2.15B | -$657.0M | -$4.99B | $2.19B | -$1.17B | -$137.0M | -$6.15B |
Dilution Tracker
Shares Outstanding
2044M
5-Year Share Growth
-9.6%
Stock Issuance (TTM)
-$26.0M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 1680.00 | 1652.00 | 1637.00 | 1712.00 | 2258.00 | 2245.00 | 2146.00 | 2078.00 | 2027.00 | 2041.00 | 2053.00 | |
| Change vs Prior % | — | -1.7% | -0.9% | 4.6% | 31.9% | -0.6% | -4.4% | -3.2% | -2.5% | 0.7% | 0.6% | |
| Stock Issuance | $181.0M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$106.0M | -$128.0M | -$26.0M | |
| Stock Repurchase | -$231.0M | -$2.47B | -$320.0M | -$7.30B | -$1.55B | -$6.29B | -$8.00B | -$5.16B | $0.00 | $0.00 | -$98.0M | |
| Stock Based Comp. | $205.0M | $199.0M | $221.0M | $441.0M | $779.0M | $583.0M | $457.0M | $518.0M | $507.0M | $553.0M | $552.0M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 74.4% | 71.1% | 71.3% | 69.1% | 72.3% | 78.6% | 78.0% | 76.2% | 71.1% | 71.1% | 69.2% | |
| Operating Margin % | 23.0% | 16.6% | 22.7% | 22.6% | 5.1% | 18.4% | 19.7% | 18.2% | 12.2% | 28.5% | 26.1% | |
| Net Margin % | 22.9% | 4.8% | 21.8% | 13.2% | -21.2% | 15.1% | 13.7% | 17.8% | -18.5% | 14.6% | 18.5% | |
| EBITDA Margin % | 33.3% | 29.4% | 30.1% | 28.2% | 11.6% | 43.4% | 41.6% | 43.0% | 6.6% | 31.6% | 30.3% | |
| FCF Margin % | 9.5% | 20.3% | 27.1% | 28.2% | 31.3% | 32.8% | 25.9% | 28.1% | 28.9% | 26.7% | 18.6% | |
| ROE % | 27.6% | 8.6% | 35.1% | 6.7% | -23.8% | 19.5% | 20.4% | 27.3% | -54.8% | 38.2% | 43.9% | |
| ROA % | 13.2% | 3.0% | 14.1% | 2.6% | -7.6% | 6.4% | 6.5% | 8.4% | -9.7% | 7.8% | 10.4% | |
| ROIC % | 13.2% | 2.6% | 16.3% | 3.6% | 2.1% | 8.0% | 9.4% | 10.2% | 8.3% | 15.0% | 14.9% | |
| R&D / Revenue % | 25.8% | 31.1% | 28.1% | 23.5% | 26.2% | 22.0% | 20.6% | 20.7% | 23.1% | 20.6% | 21.1% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17.3% | 6.9% | 8.6% | 15.9% | 62.6% | 9.1% | -0.5% | -2.5% | 7.3% | -0.2% | |
| Gross Profit | 14.3% | 2.1% | 9.0% | 12.3% | 70.2% | 18.5% | -1.2% | -4.7% | 0.1% | -0.2% | |
| Operating Income | 158.2% | -22.9% | 48.4% | 15.6% | -63.2% | 292.1% | 6.6% | -10.0% | -28.2% | 133.1% | |
| Net Income | 184.8% | -77.4% | 388.6% | -30.1% | -362.1% | 177.6% | -9.5% | 26.8% | -211.5% | 178.8% | |
| EPS (Diluted) | 173.2% | -77.0% | 396.7% | -33.7% | -298.0% | 178.4% | -5.4% | 30.8% | -214.2% | 178.2% | |
| Operating Cash Flow | 45.3% | 72.5% | 34.0% | 16.2% | 71.2% | 15.3% | -19.4% | 6.1% | 9.6% | -6.8% | |
| Free Cash Flow | 43.4% | 129.0% | 44.9% | 20.6% | 80.3% | 14.5% | -21.6% | 5.9% | 10.2% | -7.9% | |
| R&D Expense | -15.3% | 29.1% | -2.1% | -2.9% | 81.2% | -8.5% | -6.7% | -2.2% | 20.0% | -10.8% | |
| SG&A Expense | -0.4% | -4.6% | -4.2% | 7.0% | 57.3% | 0.4% | 1.6% | -0.5% | 8.3% | -13.6% | |
| Total Assets | 6.2% | -0.5% | 4.3% | 271.4% | -8.8% | -7.7% | -11.4% | -1.7% | -2.7% | -2.8% | |
| Book Value / Share | 13.1% | -26.4% | 20.1% | 250.5% | -44.7% | -3.4% | -9.9% | -2.5% | -43.3% | 12.1% | |
| Debt | 0.3% | 18.7% | -7.7% | 546.9% | 8.7% | -11.8% | -10.7% | 1.8% | 23.5% | -7.9% | |
| Diluted Shares | 0.1% | -1.7% | -0.9% | 4.6% | 31.9% | -0.6% | -4.4% | -3.2% | -2.5% | 0.7% |
Valuation
P/E (TTM)13.75
10Y Low / Med / High13.22 / 21.89 / 100.46
P/S2.54
10Y Low / Med / High2.28 / 3.32 / 5.03
P/B5.42
10Y Low / Med / High2.12 / 5.96 / 8.59
EV/EBITDA10.71
10Y Low / Med / High7.03 / 15.49 / 49.08
EV/Revenue3.24
10Y Low / Med / High3.03 / 4.00 / 5.53
P/FCF13.68
10Y Low / Med / High8.22 / 12.83 / 52.99
Intrinsic Value Models (per share)
DCF Value
$239.82
Graham Number
$34.15
Cash / Share
$6.16
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | 21.89 | 100.46 | 17.16 | 31.78 | -15.59 | 19.79 | 24.23 | 13.22 | -12.83 | 15.59 | 13.75 | |
| P/S Ratio | 5.03 | 4.85 | 3.76 | 4.19 | 3.29 | 2.99 | 3.32 | 2.36 | 2.37 | 2.28 | 2.54 | |
| P/B Ratio | 6.04 | 8.59 | 6.05 | 2.12 | 3.70 | 3.85 | 4.93 | 3.61 | 7.02 | 5.96 | 5.42 | |
| EV/EBITDA | 15.49 | 16.90 | 12.57 | 19.61 | 35.95 | 8.45 | 9.62 | 7.03 | 49.08 | 9.65 | 10.71 | |
| EV/Revenue | 5.15 | 4.97 | 3.78 | 5.53 | 4.17 | 3.67 | 4.00 | 3.03 | 3.22 | 3.05 | 3.24 |
Analyst Estimates & Quality
Altman Z-Score
2.70
Grey Zone
Piotroski F-Score
7
Strong
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $50.11B | $48.74B | $40.64B |
| Net Income | $13.21B | $13.63B | $10.89B |
| EPS | $6.44 | $6.66 | $5.33 |
| # Analysts (EPS) | 15 | 16 | 8 |
Dividends
Dividend/Share (TTM)
$2.52
Dividend Yield
4.06%
Frequency
Quarterly
Recent Payments
| Ex-Date | Pay Date | Amount | Frequency |
|---|---|---|---|
| Oct 2, 2026 | Nov 2, 2026 | $0.63 | Quarterly |
| Jul 2, 2026 | Aug 3, 2026 | $0.63 | Quarterly |
| Apr 2, 2026 | May 1, 2026 | $0.63 | Quarterly |
| Jan 2, 2026 | Feb 2, 2026 | $0.63 | Quarterly |
| Oct 3, 2025 | Nov 3, 2025 | $0.62 | Quarterly |
| Jul 3, 2025 | Aug 1, 2025 | $0.62 | Quarterly |
| Apr 4, 2025 | May 1, 2025 | $0.62 | Quarterly |
| Jan 3, 2025 | Feb 3, 2025 | $0.62 | Quarterly |
| Oct 4, 2024 | Nov 1, 2024 | $0.60 | Quarterly |
| Jul 5, 2024 | Aug 1, 2024 | $0.60 | Quarterly |
| Apr 4, 2024 | May 1, 2024 | $0.60 | Quarterly |
| Jan 4, 2024 | Feb 1, 2024 | $0.60 | Quarterly |
| Oct 5, 2023 | Nov 1, 2023 | $0.57 | Quarterly |
| Jul 6, 2023 | Aug 1, 2023 | $0.57 | Quarterly |
| Apr 6, 2023 | May 1, 2023 | $0.57 | Quarterly |
| Jan 5, 2023 | Feb 1, 2023 | $0.57 | Quarterly |
| Oct 6, 2022 | Nov 1, 2022 | $0.54 | Quarterly |
| Jun 30, 2022 | Aug 1, 2022 | $0.54 | Quarterly |
| Mar 31, 2022 | May 2, 2022 | $0.54 | Quarterly |
| Jan 6, 2022 | Feb 1, 2022 | $0.54 | Quarterly |
Revenue Segments
By Product
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Abraxane | $1.25B | $1.18B | $811.0M | $1.00B | $875.0M | $368.0M |
| Baraclude | $447.0M | — | — | — | — | — |
| Eliquis | $9.17B | $10.76B | $11.79B | $12.21B | $13.33B | $14.44B |
| Empliciti | $381.0M | — | — | — | — | — |
| Mature Products And All Other | $1.31B | $1.90B | $1.75B | — | — | — |
| Opdivo | $6.99B | $7.52B | $8.25B | $9.01B | $9.30B | $10.05B |
| Orencia | $3.16B | $3.31B | $3.46B | $3.60B | $3.68B | $3.71B |
| Pomalyst/Imnovid | $3.07B | $3.33B | $3.50B | $3.44B | $3.54B | $2.73B |
| Reblozyl | $274.0M | $551.0M | $717.0M | $1.01B | $1.77B | $2.33B |
| Revlimid | $12.11B | $12.82B | $9.98B | $6.10B | $5.77B | $2.95B |
| Sprycel | $2.14B | $2.12B | $2.17B | $1.93B | $1.29B | $493.0M |
| Yervoy | $1.68B | $2.03B | $2.13B | $2.24B | $2.53B | $2.90B |
| Zeposia | $12.0M | $134.0M | $250.0M | $434.0M | $566.0M | $577.0M |
| Abecma | — | $164.0M | $388.0M | $472.0M | $406.0M | $427.0M |
| Breyanzi | — | $87.0M | $182.0M | $364.0M | $747.0M | $1.36B |
| Camzyos | — | — | $24.0M | $231.0M | $602.0M | $1.07B |
| Opdualag | — | — | $252.0M | $627.0M | $928.0M | $1.19B |
| Sotyktu | — | — | $8.0M | $170.0M | $246.0M | $291.0M |
| Cobenfy | — | — | — | — | $10.0M | $155.0M |
| Krazati | — | — | — | — | $126.0M | $205.0M |
| Other Growth Brands | — | — | — | — | $1.60B | $1.92B |
| Other Legacy Brands | — | — | — | — | $925.0M | $798.0M |
| Opdivo Ovantig | — | — | — | — | — | $238.0M |
By Geography
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Europe | $9.85B | $10.69B | $13.50B | — | — | — |
| Other Region | $631.0M | $852.0M | $834.0M | $699.0M | $996.0M | $1.09B |
| Rest Of World | $5.46B | $5.63B | — | $12.75B | $13.20B | — |
| UNITED STATES | $26.58B | $29.21B | $31.83B | $31.55B | $34.10B | $33.28B |